Cell Genesys terminates Vital-1 Phase III prostate cancer trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      CELL Genesys Inc. 609631569 CEGE
    • Abstract:
      The article reports on the termination of Phase III prostate cancer trial conducted by Cell Genesys Inc. The biotechnology company has ended the Vital-1 Phase III clinical trial of Gvax immunotherapy in patients with asymptomatic hormone-refractory prostate cancer. The company ended the trial based on the results of futility analysis carried by the study's independent data monitoring committee (IDMC) which showed that the trial had less than a 30% chance to meet its predefined primary endpoints.